close

Вход

Забыли?

вход по аккаунту

В КНИТУ-КАИ обсудили развитие электронных технологий;pdf

код для вставкиСкачать
I : šª·Á‡¦µ´®r¨´­³ŠÁ‡¦µ´®rŠµœª·‹³¥­³˜ªrže„Äœž¦´Áš«Åš¥ (2530-2549)
o°Š¤µ« ¨³‡–³ (2547) ŗošÎµ„µ¦«¹„¬µÁž¦¸¥Áš¸¥„µ¦ª·œ·‹Œ´¥Ã¦‡¡µ¦rêŪ¦´­Äœ®nµœÂ¨³Áž}—Áš« (Goose
and Muscovy duck parvovirus, GPV/MDPV) —oª¥ª·›¸ direct fluorescent antibody test (dFA) „´„µ¦Â¥„ÁºÊ°Åª¦´­ÄœÅ…n
Áž}—Áš«¢{„ ×¥Ÿ¨¡ªnµ­µ¤µ¦™˜¦ª‹¡Åª¦´­ —oª¥ª·›¸ dFA ĜÁž}—š¸É°µ¥»œo°¥„ªnµ 1.5 Á—º°œ ‹Îµœªœ 91% …¹ÊœÅž …–³š¸É
Áž}—°µ¥» 1.5-2 Á—º°œ ˜¦ª‹¡Åª¦´­Á¡¸¥Š 66.67% …–³š¸Éª·›¸„µ¦Â¥„ÁºÊ°Åª¦´­ÄœÅ…nÁž}—Áš«œ´Êœ ­µ¤µ¦™Â¥„ÁºÊ°Åª¦´­Å—o‹µ„
Áž}—š»„˜´ª °¥nµŠÅ¦„Șµ¤ª·›¸ÄoŅnÁž}—Áš«¢{„¤¸‡ªµ¤Åª­¼Š„ªnµª·›¸ dFA ˜nĜ¨¼„Áž}—š¸Éžiª¥Äœ¦³¥³Â¦„…°Š„µ¦Áž}œÃ¦‡ª·›¸
dFA Ä®oŸ¨¦ª—Á¦ÈªÂ¨³¤¸‡nµÄo‹nµ¥˜É優nµ
3. æ‡Åª¦´­˜´°´„Á­ÄœÁž}— (Duck viral hepatitis)
æ‡Åª¦´­˜´°´„Á­ÄœÁž}—¡Å—oš´ÉªÅž ­Îµ®¦´ž¦³Áš«Åš¥¡„µ¦¦µ¥Šµœ…°ŠÃ¦‡Á¡¸¥Š 1 ¦µ¥Šµœ
„µ¦Â¥„¨³¡·­¼‹œrÁºÊ°Åª¦´­˜´°´„Á­Äœ¨¼„Áž}—Ž¹ÉŠžiª¥Â¨³˜µ¥ ×¥šÎµ„µ¦Â¥„ÁºÊ°Åª¦´­—oª¥„µ¦Äo˜´— 20 %
suspension Œ¸—Á…oµÅ„nŅn¢{„ ¨³Å…nÁž}—¢{„ ŸnµœÁŽ¨¨rÁ¡µ³Á¨¸Ê¥Šš¸ÉÁ˜¦¸¥¤‹µ„‡´¡£³Áž}— ¨³Œ¸—¨¼„Áž}—š—¨°Šš¸Éŗo¦´ ¨³
Ťnŗo¦´ª´‡Ž¸œžj°Š„´œÃ¦‡Åª¦´­˜´°´„Á­ÄœÁž}—¦ª¤š´ÊŠ¡·­¼‹œrÁºÊ°Åª¦´­š¸ÉÂ¥„Å—o×¥ª·›¸œ·ªš¦µ¨Å¨ÁŽ´Éœ ¡ªnµÁºÊ°Åª¦´­
šÎµÄ®o‡´¡£³Å„n˜µ¥¤¸¨´„¬–³ hemorrhage ¨³ª¤œÊε ­nªœ‡´¡£³Áž}—¡ÁŒ¡µ³ hemorrhage ¨¼„Áž}—š—¨°Šš¸Éŗo¦´ª´‡Ž¸œ
­µ¤µ¦™‡»o¤Ã¦‡Å—o ­nªœ¨¼„Áž}—š—¨°Šš¸ÉŤnŗo¦´ª´‡Ž¸œ­µ¤µ¦™‡»o¤Ã¦‡Å—o ­nªœ¨¼„Áž}—š—¨°Šš¸ÉŤnŗo¦´ª´‡Ž¸œ˜µ¥ 60 –
80% Ÿ¨„µ¦¡·­¼‹œrÁºÊ°Åª¦´­š¸ÉÂ¥„Å—o¥ºœ¥´œªnµÁž}œÁºÊ°Åª¦´­˜´°´„Á­ÄœÁž}— (¡¦š·¡¥r ¨³‡–³, 2540)
懘·—ÁºÊ°Â‡š¸Á¦¸¥…°ŠÁž}—¨³®nµœ
1. 懘·—ÁºÊ°Å¦Á¤°¦rÁ¦¨nµ®¦º°œ·ª—´Ë„Ž·œÃ—¦¤ (Riemerella infection or new duck syndrome)
懘·—ÁºÊ°Å¦Á¤°¦rÁ¦¨nµ Á„·—‹µ„ÁºÊ°Â‡š¸Á¦¸¥ Riemerella anatipestifer ­µ¤µ¦™¡Å—oš´ÊŠÄœÁž}—¨³®nµœ ­´˜ªr°µ¥»
œo°¥Åª˜n°„µ¦Áž}œÃ¦‡¤µ„ªnµ­´˜ªr°µ¥»¤µ„ Ĝ°—¸˜ÁºÊ°œ¸Ê™¼„‹´—°¥¼nĜ„¨»n¤ Pasteurella anatipestifer °´˜¦µžiª¥Â¨³˜µ¥­¼Š
¨¼„Áž}—š¸Éžiª¥˜µ¥ Á¤ºÉ°œÎµ¤µŸnµŽµ„‹³¡¨´„¬–³Å¢¦·œž„‡¨»¤°ª´¥ª³£µ¥Äœ ŗo„n ˜´ ®´ªÄ‹ n°Ššo°Š Áž}œ˜oœ ¦µ¥Šµœ
ŗo¦ª¦ª¤—oµœ¡¥µ›·­£µ¡…°ŠÃ¦‡ ¦µ¥Šµœ„µ¦¦³µ—…°ŠÃ¦‡ „µ¦žj°Š„´œÂ¨³¦´„¬µ‡»–¨´„¬–³…°ŠÁºÊ° Áž}œ˜oœ ¦ª¤
š´ÊŠ®¤— 8 ¦µ¥Šµœ —´Šœ¸Ê
„µ¦«¹„¬µ„µ¦¦³µ—…°Š„µ¦˜·—ÁºÊ° Anatipestifer
ĜÁž}—…°Šž¦³Áš«Åš¥ 懜¸ÊÁ„·—‹µ„ÁºÊ° Pasteurella
anatipestifer ĜÁž}—¦³®ªnµŠ ˜»¨µ‡¤ 1988 – „¦„‘µ‡¤ 1989 ‹Îµœªœ 20 ¼Š ¦ª¤ 66,000 ˜´ª °µ¥»¦³®ªnµŠ 1 ª´œ – 18 Á—º°œ
Ž¹ÉŠÂ­—Š°µ„µ¦¦³šµŠÁ—·œ®µ¥Ä‹ ˜µÂŒ³ œÊε¤¼„ …¸ÊÁ…¸¥ª ®¦º° …¸Ê…µª ¤¸°µ„µ¦šµŠž¦³­µš ‡°·—®Šœ—¼—µª ­µ¤µ¦™Â¥„
ÁºÊ°œ¸Êŗo‹µ„°ª´¥ª³£µ¥Äœ ¨³­¤°Š ¨³ÁºÊ°š¸ÉÂ¥„Å—o š»„ÁºÊ°¤¸‡ªµ¤Åª˜n°¥µ cephalexin, cephaloridine, erythromycin,
oleandomycin, tetracycline ¨³ dimethylchlorotetracycline (Pornpen et al., 1990)
¡¦Á¡È ¨³‡–³ (2534) ŗošÎµ„µ¦«¹„¬µ‡»–­¤´˜·Â¨³‡ªµ¤Åª˜n°¥µ˜oµœ‹»¨¸¡…°ŠÁºÊ° Pasteurella anatipestifer
š¸ÉÂ¥„Å—o‹µ„Áž}—Äœž¦³Áš«Åš¥š¸ÉÁ„·—¦³µ—¦³®ªnµŠÁ—º°œ˜»¨µ‡¤ 2531 – „¦„‘µ‡¤ 2532 ‹Îµœªœ 20 Á­˜¦œ ¡ªnµÁºÊ°š»„
Á­˜¦œ¤¸‡ªµ¤Åª˜n°¥µ cephalexin, cephaloridin, erythromycin, olendomycin, tetracycline ¨³ dimethylchlorotetracycline
‹µ„„µ¦­´ŠÁ„˜¡ªnµ ¥µš¸ÉšµŠ‡–³Ÿ¼oª·‹´¥Á¨º°„čoœ´Êœ ¥µš¸É¤¸„µ¦Äo‹¦·ŠÄœ„µ¦¦´„¬µ­nªœ¤µ„‹³—ºÊ°˜n°¥µš¸Éčoš—­° ŗo„n
bacitracin, streptomycin, sulfamonomethoxin Áž}œ˜oœ
273
„µ¦¦ª¦ª¤ª·Á‡¦µ´®r¨´­³ŠÁ‡¦µ´®rŠµœª·‹³¥­³˜ªrže„Äœž¦´Áš«Åš¥ (2530-2549)
¦µ¥Šµœ­´˜ªržiª¥ : „µ¦¦³µ—…°ŠÃ¦‡ Aspergillosis ¡¦o°¤„´ anatipestifer ĜÁž}— Babery ¡„µ¦¦³µ—Äœ ¼Š
Áž}—°µ¥» 1 ­´ž—µ®r ¡°´˜¦µ„µ¦˜µ¥ 24.8% ‹µ„ 3,280 ˜´ª ×¥¡¦°¥Ã¦‡˜»n¤…µª°¤Á®¨º°Š ¦·Áª–ÁœºÊ°Á¥ºÉ°ž°— …œµ— 1-4
¤.¤. ¡¨´„¬–³ focal pneumonia ¨³¥´Š¡¦°¥Ã¦‡Äœn°Ššo°Š ÁœºÊ°Á¥ºÉ°­¤°Š ¨³˜n°¤Á°¦rŽnµ ‹µ„„µ¦˜¦ª‹¡šµŠ
‹»¨¡¥µ›·ª·š¥µ ¡¨´„¬–³Â„¦œ¼Ã¦¤µ ¨³ giant cells ¨³ mycelia £µ¥ÄœÂ„¦œ¼Ã¦¤µ Ž¹ÉŠ¡ªnµÁž}œ Aspergillus fumigatus
œ°„‹µ„œ¸Ê­µ¤µ¦™Â¥„ÁºÊ°Â‡š¸Á¦¸¥ Pasteurella anatipestifer ‹µ„ÁœºÊ°Á¥ºÉ°ž°— Ž¹ÉŠ¤¸„µ¦¦´„¬µ—oª¥„µ¦Œ¸— oxytetracycline
¡¦o°¤„´„µ¦¨³¨µ¥ sulfatrimethoprim ĜœÊε„·œ Ž¹ÉŠnª¥¨—‡ªµ¤­¼Á­¸¥¨ŠÅ—o (¨´——µ ¨³‡–³, 2538)
¡Ž¸Ã¦ÅšžmÄ®¤n…°Š Riemerella anatipestifer ‹µ„Áž}—Äœž¦³Áš«Åš¥ ×¥¡Ž¸Ã¦ÅšžmÄ®¤n ‡º° Ž¸Ã¦Åšžm 20
¨³ 21 ÁœºÉ°Š‹µ„Ťn¤¸ž’·„·¦·¥µ˜n°Â°œ˜·Ž¸¦´É¤¤µ˜¦“µœš´ÊŠ 19 Ž¸Ã¦Åšžm ÁºÊ°­nªœ¤µ„š¸É¡Áž}œŽ¸Ã¦Åšžm 1(56.3%) ‹µ„
‹Îµœªœš´ÊŠ­·Êœ 29 Á­˜¦œ (¡¦Á¡È ¨³‡–³, 2538)
Pornpen et al. (1996)ŗošÎµ„µ¦«¹„¬µª´‡Ž¸œš¸ÉÁ˜¦¸¥¤…¹Êœ‹µ„ broth culture bacterin ¨³ cell-free culture filtrate
(Ťn¤¸ÁŽ¨¨r…°ŠÂ‡š¸Á¦¸¥) …°Š Riemerella anatipestifer œÎµ¤µš—­°„´Áž}—°µ¥» 2 ­´ž—µ®r ¡´œ›»r Khaki Campbell
£µ¥®¨´Š‹µ„„µ¦Ä®oª´‡Ž¸œÂ‡š¸¦·œ ®¦º° cell-free culture filtrate ¨oªÄ®oÁºÊ°¡·¬š´—oª¥ÁºÊ°Á­˜¦œÁ—¸¥ª„´š¸ÉœÎµ¤µšÎµª´‡Ž¸œ
nªŠÁª¨µ˜nµŠÇ Ÿ¨¡ªnµ Áž}—Ä®o—´œ¸‡ªµ¤‡»o¤Ã¦‡ (protective index;PI) 66.7-100 ×¥ PI ­¼Š­»—ÄœnªŠ£µ¥®¨´Š¦´ª´‡Ž¸œ
¨oª 2 ­´ž—µ®r Ž¹ÉŠ„µ¦«¹„¬µ‡¦´ÊŠœ¸Ê¡ªnµÅ¤n­µ¤µ¦™žj°Š„´œÃ¦‡Å—o ®µ„Ä®oÁºÊ°¡·¬š´˜nµŠÁ­˜¦œ„´ª´‡Ž¸œš¸ÉœÎµ¤µÁ˜¦¸¥¤
°Š‡rž¦³„°…°ŠÂ°œ˜·Á‹œš¸É¤¸Ÿ¨Äœ„µ¦­¦oµŠ‡ªµ¤‡»o¤Ã¦‡˜n° Riemerella anatipestifer „µ¦«¹„¬µ‡¦´ÊŠœ¸ÊÁ˜¦¸¥¤
ÁºÊ° R. anatipestifer Á­˜¦œ 1081 Ž¸Ã¦Åšžm 1 ĜÁž}— ץčo­nªœÃž¦˜¸œ„¹ÉŠ¦·­»š›·Íš¸É˜„˜³„°œÃ—¥ ammonium sulfate
¨³­„´——oª¥ Sephadex G-200 gel filtration ª´‡Ž¸œš¸É¤¸Ãž¦˜¸œ 100 mg ¨³¤¸°¨¼¤·Áœ¸¥¤Å±—¦°„ÅŽ—r°¥¼n 25% šÎµ®œoµš¸ÉÁž}œ
°—‹¼Âªœšr œÎµ¤µšÎµª´‡Ž¸œÂ„nÁž}—š¸É°µ¥» 14 ª´œ Á…oµÄ˜oŸ·ª®œ´ŠÂ¨³š—­°‡ªµ¤‡»o¤Ã¦‡ ×¥„µ¦Œ¸—ÁºÊ°¡·¬š´—oª¥ÁºÊ°
—´Š„¨nµªš¸É°µ¥» 35 ª´œ ×¥¡‡ªµ¤‡»o¤Ã¦‡ 100% °¥nµŠÅ¦„Șµ¤‡ªµ¤‡»o¤Ã¦‡‹³¨—¨Š°¥nµŠ¤¸œ´¥­Îµ‡´ Á¤ºÉ°šÎµÄ®oª´‡Ž¸œ¦o°œ
100 ÎC œµœ 1 ´ÉªÃ¤Š®¦º°¥n°¥—oª¥Á°œÅŽ¤r trypsin …–³š¸ÉÁ°ÈœÅŽ¤r lipase ¨—‡ªµ¤‡»o¤Ã¦‡…°Šª´‡Ž¸œÅ—ožµœ„¨µŠ°¥nµŠ¤¸
œ´¥­Îµ‡´ (p<0.05) ­—ŠÄ®oÁ®ÈœªnµÃž¦˜¸œ®¦º°­µ¦ž¦³„° peptide Áž}œ°Š‡rž¦³„°­Îµ‡´Äœ„µ¦­¦oµŠ‡ªµ¤‡»o¤Ã¦‡œ¸Ê
­nªœ lipid ¤¸Ÿ¨˜n°„µ¦­¦oµŠ‡ªµ¤‡»o¤Ã¦‡¦°Š¨Š¤µ (¡¦Á¡È ¨³‡–³, 2539)
2. 懰®·ªµ˜rÁž}—-ńn (Fowl cholera)
懰®·ªµ˜rÁž}—-ńn Á„·—‹µ„ÁºÊ°Â‡š¸Á¦¸¥ ­µ¤µ¦™¡Å—oš´ÊŠÄœÁž}— ®nµœ ¨³Å„n Ž¹ÉŠÁž}—¨³®nµœ¤¸‡ªµ¤Åª˜n°„µ¦
Áž} œÃ¦‡¤µ„„ªn µÅ„n °´ ˜¦µ„µ¦žiª¥Â¨³˜µ¥‡n °œ…o µŠ­¼ Š ­µ¤µ¦™žj °Š„´œÅ—o—oª¥„µ¦Ä®o ª´‡Ž¸ œ ­µ¤µ¦™¦´„¬µÅ—o —oª¥¥µ
ž’·¸ªœ³š¸É¤¸ž¦³­·š›·£µ¡ ¦µ¥ŠµœÅ—o¦ª¦ª¤—oµœ„µ¦žj°Š„´œ—oª¥ª´‡Ž¸œ „µ¦¦´„¬µÃ¦‡ ¦µ¥Šµœ„µ¦¦³µ—…°ŠÃ¦‡ Áž}œ˜oœ
¦ª¤š´ÊŠ®¤— 4 ¦µ¥Šµœ —´Šœ¸Ê
­»£µ¡¦ ¨³‡–³ (2530 ) šÎµ„µ¦«¹„¬µ°´˜¦µ„µ¦Á‹¦·Á˜·Ã˜…°ŠÁºÊ° Pasteurella multocida serotype 8:A Ĝ™´Š
š¸ÉÁ˜¦¸¥¤Ÿ¨·˜ª´‡Ž¸œ ×¥šÎµ„µ¦˜¦ª‹š»„‡¦¹ÉŠ®¦º° 1 ´ÉªÃ¤Š š—­°‡ªµ¤…»nœ‡ªµ¤¦·­»š›·Í ‡ªµ¤Áž}œ„¦—-—nµŠ ¨³„µ¦¦°—
¸ª·˜…°ŠÁºÊ° Ÿ¨¡ªnµÁºÊ°Â‡š¸Á¦¸¥š¸É¤¸°´˜¦µ„µ¦Á‹¦·Á˜·Ã˜Å—o—¸š¸É­»— š¸É 7-9½ ´ÉªÃ¤Š £µ¥®¨´Š„µ¦Ä­nÁºÊ°¨ŠÅž Ž¹ÉŠ¤¸
ž¦³¤µ– 1.48-2.3x1010 CFU/ml.
‡ªµ¤‡»o¤Ã¦‡Â¨³¦³—´…°ŠÂ°È‡„¨¼˜·œ·œÄœÁž}— ®¨´ŠŒ¸——oª¥ª´‡Ž¸œ°®·ªµ˜rÁž}—š¸ÉŸ­¤—oª¥Â°p—‹¼Âªœšrœ·—˜nµŠÇ
‡º° mineral-oil-adjuvanted (MDC) vaccine , corn-oil adjuvanted (CDC) vaccine ¨³ aluminium-hydroxide-absorbed
(ADC) vaccine ¨³ª´‡Ž¸œš¸ÉŤn¤¸Â°p—‹¼Âªœšr ª´‡Ž¸œš´ÊŠ®¤—Áž}œª´‡Ž¸œÁºÊ°˜µ¥ ‰nµ—oª¥¢°¦r¤µ¨·œ Áž¦¸¥Áš¸¥„´ª´‡Ž¸œ…°Š
„¦¤ž«»­´˜ªr ×¥Áž}—˜n¨³„¨»n¤Å—o¦´„µ¦Œ¸—ª´‡Ž¸œÂ˜n¨³œ·— ×¥šÎµ„µ¦Œ¸—ª´‡Ž¸œ 1 ¨³ 2 ‡¦´ÊŠ ˜¦ª‹®µ¦³—´Â°œ˜·°—¸
×¥ª·›¸ tube agglutination (TA) ¨³ indirect hemagglutination (IHA) ×¥¡ªnµ °œ˜·Á‹œš¸ÉÁ˜¦¸¥¤—oª¥ª·›¸ autoclaved
274
I : šª·Á‡¦µ´®r¨´­³ŠÁ‡¦µ´®rŠµœª·‹³¥­³˜ªrže„Äœž¦´Áš«Åš¥ (2530-2549)
antigen ­µ¤µ¦™˜¦ª‹®µ¦³—´Â°œ˜·°—¸—oª¥ª·›¸ TA ŗo—¸š¸É­»— Á¤ºÉ°Áž¦¸¥Áš¸¥„´ HCl-treated antigen, formalinized
antigen ¨³ living antigen ­nªœª·›¸ IHA ­µ¤µ¦™˜¦ª‹®µ¦³—´Â°œ˜·°—¸Å—o‡nµ­¼Š„ªnµª·›¸ TA ­Îµ®¦´Áž}—š¸Éŗo¦´ª´‡Ž¸œ
MDC ¨oª 15 ª´œ ­nªœ„¨»n¤š¸Éŗoª´‡Ž¸œ FDC ¨³ DCL Ž¹ÉŠÅ¤n¤¸ adjuvant Ÿ­¤ ¡ªnµ¦³—´Â°œ˜·°—¸š¸Éª´——oª¥ª·›¸ IHA ‹³
˜É優nµ TA ­nªœ„µ¦Å—o¦´ª´‡Ž¸œ ‡¦´ÊŠš¸É 2 ¡¦³—´Â°œ˜·°—¸˜É優nµ Á¤ºÉ°Áž¦¸¥Áš¸¥„´Å—o¦´ª´‡Ž¸œ‡¦´ÊŠÁ—¸¥ª‹µ„„µ¦˜¦ª‹
—oª¥ª·›¸ TA ˜n®µ„˜¦ª‹—oª¥ª·›¸ IHA œ´Êœ ¡Â°œ˜·°—¸­¼Š ÁŒ¡µ³Äœ„¨»n¤š¸É¤¸Â°p—‹¼Âªœšr ˜nŤn¤¸‡ªµ¤Â˜„˜nµŠšµŠ­™·˜·
(p>0.05)
‡ªµ¤‡»o¤Ã¦‡Ã—¥Œ¸—ÁºÊ°¡·¬š´ÄœnªŠÁª¨µ˜nµŠ Ç ‹µ„Ÿ¨ ¡ªnµ ª´‡Ž¸œ„¨»n¤ MDC, ADC, FDC ¨³ DCL Ž¹ÉŠ
ŗo¦´ª´‡Ž¸œÁ¡¸¥Š‡¦´ÊŠÁ—¸¥ª ¤¸‡nµ potency 85.8%, 85.8%, 85.8% ¨³ 52.4% ˜µ¤¨Îµ—´ Ĝª´œš¸É 60 ®¨´Š‹µ„Œ¸—ª´‡Ž¸œ‡¦´ÊŠ
¦„
„¨»n¤ MDC, CDC, FDC ¨³„¦¤ž«»­´˜ªrÄ®oª´‡Ž¸œ 2 ‡¦´ÊŠ ¤¸‡ªµ¤‡»o¤Ã¦‡˜¨°—¦³¥³Áª¨µ„µ¦«¹„¬µ 5½ Á—º°œ ×¥
¤¸ potency 60.8%, 65.8%, 65.8% ¨³ 85.8% ˜µ¤¨Îµ—´ (­´œ˜· ¨³‡–³, 2531)
Unchitti et al. (1992 ) ŗošÎµ„µ¦«¹„¬µ¨´„¬–³…°ŠÁºÊ° Pasteurella multocida šµŠ‡»–­¤´˜·¸ªÁ‡¤¸ ‹Îµœªœ 70
ÁºÊ° Ž¹ÉŠž¦³„°—oª¥ ‹µ„¤œ»¬¥r 17 ÁºÊ° ­»„¦ 23 ÁºÊ°Â¨³­´˜ªrže„ 30 ÁºÊ° š»„ÁºÊ°­µ¤µ¦™­¦oµŠ catalase, oxydase, indol,
nitrate reduction ¨³ ornithine decarboxylase ¨³š»„ÁºÊ°Å¤n¤¸„µ¦¥n°¥­¨µ¥ lactose, maltose ¨³ dulcitol Ž¹ÉŠnª¥Äœ„µ¦
‹ÎµÂœ„ÁºÊ°Â‡š¸Á¦¸¥œ¸Ê °¥nµŠÅ¦„Șµ¤Å¤n­µ¤µ¦™‹ÎµÂœ„œ·—…°ŠÃ±­˜r…°ŠÁºÊ°Â‡š¸Á¦¸¥
Thaveesak et al. (2003) ŗošÎµ„µ¦«¹„¬µÁ¡ºÉ°Á®œ¸É¥ªœÎµÄ®oÁ„·—ᦊ‹¤¼„°´„Á­ Ž¹ÉŠÁ„·—‹µ„ÁºÊ° Pasteurella
multocida ĜÁž}——oª¥„µ¦®¥°—‹¤¼„—oª¥ÁºÊ°œ¸Êš¸É¤¸ capsular group B somatic serotype3 Ž¹ÉŠ­µ¤µ¦™Á®œ¸É¥ªœÎµÄ®oÁ„·—ᦊ
‹¤¼„°´„Á­…¹ÊœÅ—o ˜´ÊŠÂ˜nª´œš¸É 4 ®¨´Š„µ¦Å—o¦´ÁºÊ°
3. 懇¨µ¤´¥—·Ã°Ž·­ (Chlamydiosis)
懇¨µ¤´¥—·Ã°Ž·­ Áž}œÃ¦‡š¸É­µ¤µ¦™¡ÄœÁž}— °¥nµŠÅ¦„Șµ¤ÁºÊ°œ¸Ê­µ¤µ¦™Â¡¦n˜·—˜n°­¼n‡œÅ—o ¡„µ¦¦µ¥Šµœ
Á¡¸¥Š 1 ¦µ¥Šµœ ‹µ„„µ¦˜¦ª‹—oª¥„µ¦´œ­¼˜¦Žµ„
懇¨µÅ¤—·Ã°Ž·­ÄœÁž}— (chlamydiosis) Áž}œÃ¦‡˜·—˜n°¦³®ªnµŠ­´˜ªr¨³‡œ ×¥¡ÄœÁž}—š¸É­nŠ¤µŸnµŽµ„š¸É
®œnª¥¡¥µ›·ª·š¥µ ‡–³­´˜ªÂ¡š¥«µ­˜¦r ‹»¯µ¨Š„¦–r¤®µª·š¥µ¨´¥ Ž¹ÉŠ‹µ„„µ¦ŸnµŽµ„¡¨´„¬–³š¸É­´ŠÁ„˜—oª¥˜µÁž¨nµ —´Šœ¸Ê
infraorbital sinusitis, fibrinous airsacculitis ¨³ fatty change …°Š˜´ ¨³­µ¤µ¦™¥o°¤¡ÁºÊ° Chlamydia spp. (¤µœ·˜
¨³Á¨È„, 2539)
2. ­µ¦¡·¬°³¢¨µš°„Ž·œ (Aflatoxin)
­µ¦¡·¬°³¢¨µš°„Ž·œš¸É¡Á„·—‹µ„„µ¦­¦oµŠ…°ŠÁºÊ°¦µ Aspergillus flavus ­µ¦¡·¬œ¸Ê„n°ž{®µÂ„n°»˜­µ®„¦¦¤
„µ¦Á¨¸Ê¥Š­´˜ªrš»„œ·— ­Îµ®¦´°»˜­µ®„¦¦¤„µ¦Á¨¸Ê¥Š­´˜ªrže„œ´Êœ ­µ¦¡·¬œ¸Ê„n°Ä®oÁ„·—ž{®µÁ¦ºÊ°¦´Š ­µ¦¡·¬­³­¤£µ¥Äœ
¦nµŠ„µ¥­´˜ªrže„ šÎµÄ®oÁ¤ºÉ°­´˜ªrže„Å—o¦´°´œ˜¦µ¥ ­´˜ªrže„œ´Êœ‹³Â­—Š°µ„µ¦žiª¥Â¨³˜µ¥ œ°„‹µ„œ¸Ê­µ¦¡·¬œ¸Ê¥´Š¤¸Ÿ¨˜n°„µ¦
­¦oµŠ£¼¤·‡»o¤„´œ…°Š¦nµŠ„µ¥ šÎµÄ®o¦nµŠ„µ¥˜°­œ°Š˜n°„µ¦„¦³˜»oœª´‡Ž¸œÅ¤n—¸Ášnµš¸É‡ª¦ ­Îµ®¦´­µ¦¡·¬œ¸Ê¡ªnµÁž}— ®nµœ ‹³
¤¸‡ªµ¤Åª˜n°„µ¦Áž}œ¡· ¬¤µ„„ªn µÅ„n ­´˜ªr že„ Án œÅ„n ŗo ¦´­µ¦¡·¬ œ¸Ê‹µ„„µ¦žœÁžg°œÄœ°µ®µ¦Áž}œ®¨´„ ¦µ¥ŠµœÅ—o
¦ª¦ª¤—oµœ„µ¦˜¦ª‹ª·œ·‹Œ´ ¥­µ¦¡· ¬°³¢¨µšp° „Ž· œ ¦³—´ š¸É˜¦ª‹¡­µ¦¡·¬ÄœŸ¨·˜£´–”r ¦³—´…°Š­µ¦¡·¬š¸ÉÁž}œ
°´œ˜¦µ¥ Ÿ¨…°Š­µ¦¡·¬œ¸Ê˜n°„µ¦Á‹¦·Á˜·Ã˜Â¨³˜n°¦³—´£¼¤·‡»o¤„´œ…°Š¦nµŠ„µ¥ Áž}œ˜oœ ¦ª¤š´ÊŠ®¤— 11 ¦µ¥Šµœ —´Šœ¸Ê
275
1/--страниц
Пожаловаться на содержимое документа